e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Cystic fibrosis: of exercise, aerosol and more
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison between two protocols of preventing treatment of chronic
Pseudomonas aeruginosa
(
Pa
) infection
R. Casciaro, A. De Alessandri, F. Lugani, E. Poggi, C. Gardella, G. Manno, L. Giampietri, M. Mentasti, R. Lorini (Genoa, Italy)
Source:
Annual Congress 2005 - Cystic fibrosis: of exercise, aerosol and more
Session:
Cystic fibrosis: of exercise, aerosol and more
Session type:
Thematic Poster Session
Number:
3945
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Casciaro, A. De Alessandri, F. Lugani, E. Poggi, C. Gardella, G. Manno, L. Giampietri, M. Mentasti, R. Lorini (Genoa, Italy). Comparison between two protocols of preventing treatment of chronic
Pseudomonas aeruginosa
(
Pa
) infection. Eur Respir J 2005; 26: Suppl. 49, 3945
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
Antibiotic efficacy varies based on the infection model and treatment regimen for
Pseudomonas aeruginosa
Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018
Year: 2020
Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model
Source: Eur Respir J 2007; 29: 965-968
Year: 2007
An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by
Pseudomonas aeruginosa
Source: Eur Respir J 2005; 26: Suppl. 49, 187s
Year: 2005
Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo
Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Year: 2017
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD.
Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond
Year: 2020
Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012
Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response
Source: Eur Respir J 2007; 30: 1167-1172
Year: 2007
Dental units as infection sources of Pseudomonas aeruginosa
Source: Eur Respir J 2008; 32: 1122-1123
Year: 2008
The effect of clarithromycin on immunity of mice with chronic respiratory infection caused by
P. aeruginosa
Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi
Year: 2008
Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105
Year: 2006
Can LCI predict new Pseudomonas aeruginosa colonization among CF patients?>
Source: International Congress 2017 – What is the future for paediatric respiratory physiology and sleep?
Year: 2017
The independent contribution of
Pseudomonas aeruginosa
infection to long-term clinical outcomes in bronchiectasis
Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017
Year: 2018
The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004
Pseudomonas aeruginosa
in patients with cystic fibrosis - a comparison of early eradication and conventional therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 385s
Year: 2004
Early re-colonization with
pseudomonas aeruginosa
(PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008
Does a single Pseudomonas aeruginosa isolation predict COPD mortality?
Source: Eur Respir J 2014; 44: 794-797
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept